These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31924670)

  • 1. Injured Podocytes Are Sensitized to Angiotensin II-Induced Calcium Signaling.
    Binz-Lotter J; Jüngst C; Rinschen MM; Koehler S; Zentis P; Schauss A; Schermer B; Benzing T; Hackl MJ
    J Am Soc Nephrol; 2020 Mar; 31(3):532-542. PubMed ID: 31924670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II induces calcium/calcineurin signaling and podocyte injury by downregulating microRNA-30 family members.
    Zhao Y; Wu J; Zhang M; Zhou M; Xu F; Zhu X; Zhou X; Lang Y; Yang F; Yun S; Shi S; Liu Z
    J Mol Med (Berl); 2017 Aug; 95(8):887-898. PubMed ID: 28540409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Endocytosis of Clathrin-Mediated Angiotensin II Receptor Type 1 in Podocytes Augments Glomerular Injury.
    Inoue K; Tian X; Velazquez H; Soda K; Wang Z; Pedigo CE; Wang Y; Cross E; Groener M; Shin JW; Li W; Hassan H; Yamamoto K; Mundel P; Ishibe S
    J Am Soc Nephrol; 2019 Dec; 30(12):2307-2320. PubMed ID: 31511362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.
    Nijenhuis T; Sloan AJ; Hoenderop JG; Flesche J; van Goor H; Kistler AD; Bakker M; Bindels RJ; de Boer RA; Möller CC; Hamming I; Navis G; Wetzels JF; Berden JH; Reiser J; Faul C; van der Vlag J
    Am J Pathol; 2011 Oct; 179(4):1719-32. PubMed ID: 21839714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1.
    Ren Z; Liang W; Chen C; Yang H; Singhal PC; Ding G
    Cell Signal; 2012 Feb; 24(2):443-450. PubMed ID: 21982880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent.
    Matsusaka T; Asano T; Niimura F; Kinomura M; Shimizu A; Shintani A; Pastan I; Fogo AB; Ichikawa I
    Hypertension; 2010 Apr; 55(4):967-73. PubMed ID: 20142565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diversities of podocyte molecular changes induced by different antiproteinuria drugs.
    Xing Y; Ding J; Fan Q; Guan N
    Exp Biol Med (Maywood); 2006 May; 231(5):585-93. PubMed ID: 16636307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
    Fukuda A; Fujimoto S; Iwatsubo S; Kawachi H; Kitamura K
    Nephrology (Carlton); 2010 Apr; 15(3):321-6. PubMed ID: 20470301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of nephrin phosphorylation inducted by dexamethasone and angiotensin II in podocytes.
    Yu M; Ren Q; Yu SY
    Mol Biol Rep; 2014 Jun; 41(6):3591-5. PubMed ID: 24515388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of nephrin in podocyte injury induced by angiotension II.
    Yu S
    J Recept Signal Transduct Res; 2016; 36(1):1-5. PubMed ID: 25264225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-1 receptor signaling in podocytes limits susceptibility to glomerular damage.
    Ren J; Lu X; Hall G; Privratsky JR; Robson MJ; Blakely RD; Crowley SD
    Am J Physiol Renal Physiol; 2022 Feb; 322(2):F164-F174. PubMed ID: 34894725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS.
    Gyarmati G; Shroff UN; Izuhara A; Deepak S; Komers R; Bedard PW; Peti-Peterdi J
    JCI Insight; 2024 Sep; 9(19):. PubMed ID: 39226116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II Type I Receptor Agonistic Autoantibody Induces Podocyte Injury via Activation of the TRPC6- Calcium/Calcineurin Pathway in Pre-Eclampsia.
    Yu Y; Zhang L; Xu G; Wu Z; Li Q; Gu Y; Niu J
    Kidney Blood Press Res; 2018; 43(5):1666-1676. PubMed ID: 30380548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
    Nakhoul F; Ramadan R; Khankin E; Yaccob A; Kositch Z; Lewin M; Assady S; Abassi Z
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
    Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
    J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inducible podocyte injury and proteinuria in transgenic zebrafish.
    Zhou W; Hildebrandt F
    J Am Soc Nephrol; 2012 Jun; 23(6):1039-47. PubMed ID: 22440901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Losartan reverses glomerular podocytes injury induced by AngII via stabilizing the expression of GLUT1.
    Yu SY; Qi R; Zhao H
    Mol Biol Rep; 2013 Nov; 40(11):6295-301. PubMed ID: 24062074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huangqi Guizhi Wuwu Decoction attenuates Podocyte cytoskeletal protein damage in IgA nephropathy rats by regulating AT1R/Nephrin/c-Abl pathway.
    Liu W; Shi L; Wan Q; Wu Y; Huang D; Ou J; Liu Q; Guan X; Yang Y; Zhang X; Gao J
    Biomed Pharmacother; 2021 Oct; 142():111907. PubMed ID: 34339916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species.
    van den Hoven MJ; Waanders F; Rops AL; Kramer AB; van Goor H; Berden JH; Navis G; van der Vlag J
    Nephrol Dial Transplant; 2009 Sep; 24(9):2637-45. PubMed ID: 19429930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IP
    Xu H; Guan N; Ren YL; Wei QJ; Tao YH; Yang GS; Liu XY; Bu DF; Zhang Y; Zhu SN
    BMC Nephrol; 2018 Jun; 19(1):140. PubMed ID: 29907098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.